Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Renowned Speakers

IKRAM-UL-HAQ

IKRAM-UL-HAQ

Director (ORIC)
GC University
Pakistan

Arup Ghosh

Arup Ghosh

Senior Scientist
CSIR-Central Salt & Marine Chemicals Research Institute (CSMCRI)
India

Stoffer Loman

Stoffer Loman

Senior consultant
Nutriclaim
Netherlands

Mona Zayed

Mona Zayed

Associate Professor
Ain Shams University
Egypt

El Hafid Nabti

El Hafid Nabti

Professor
University of Bejaia
Algeria

Microbiome R&D 2018

About Conference


International Conference on Microbiome R&D and Biostimulus is scheduled to be held during October 15-16, 2018 at Ottawa, Canada. This  Microbiome R&D 2018 anticipates more than 200 participants around the globe with thought provoking Keynote lectures, Oral talks and Poster presentations, Symposia, Workshops, Exhibitions and Career development programs. The attending delegates include Editorial Board Members of related ConferenceSeries Journals. This is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists. The intending participants can confirm their participation by registering at Microbiome R&D 2018 along with your colleagues. 

Microbiome R&D 2018 is one of the well-established conferences among Microbiology Conferences organized by Conference series

Conference series  Organizes 3000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals  which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conferences organize worldwide.

Why to Attend???

Microbiome R&D 2018 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about microbiology research and its advances. This is your best opportunity to reach the largest assemblage of participants from microbiology community that is from academia, microbiology entities, medical groups, labs, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries.. This conference conduct presentations, distribute information, meet with current and potential scientists, make a splash with new clinical research developments, and receive name recognition at this 2-days event. World renowned speakers and the most recent techniques, developments, the newest updates in Microbiome R&D are hallmarks of this conference.

Who Should Attend and Who You’ll Meet

Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of

  • Microbiology Research Sites
  • Pathologists and Immunologists
  • Research Scientists
  • Pharma/Biotech and Medical Device industries
  • Hospitals, Labs & Associations
  • Horticulture specialists
  • Arborists
  • Farm technicians
  • Hydroponics Growers
  • Environmental specialists

Medical Directors, Principal Investigators, Methodologists, and other clinical research professionals along with Academicians: University Faculties like Directors, Senior Professors/Assistant Professors/ Associate Professor, Research Scholars, investors, scientists who are related to Microbiome R&D. Pathologists, Doctors, Director and Managers from business organizations.

Benefits of attending Microbiome R&D Conference ?

·  An opportunity to meet the mentors across the world face-to-face.

·  Sharing ideas, challenges and plan something interesting for future

·  B2B Meetings.

·  To meet the experts in the field of Microbiome R&D.

·  To share the knowledge with doctors and Scientists.

·  To gain advance knowledge in Microbiome R&D.

·  To meet investors from different sector of Healthcare.

·  To develop collaborations between Acaemic and Business.

·  Thought provoking talks by Doctors,Professors,PhD's and Young Researchers.

Sessions/Tracks

Microbiome R&D 2018 ardently encourages patrons, benefactors, pioneers, and exhibitors from across the world to convene you all to attend and register for the “International Conference on Microbiome R&D and Biostimulants (Microbiome R&D 2018) which is going to be venerated from October 15-16, 2018 at Ottawa, Canada.

The organizing committee is endowing for a rather stimulating and illuminative conference programs subsuming Plenary Lectures, Symposia, Workshops on a myriad of topics, Poster Presentations and an assortment of programs for participants from over the globe. We invite you to accompany us at the  Microbiome R&D  2018, where you are assured to have a substantially worthwhile experience with ecumenical scholars.

Myocardial infarction and gut microbiota: An incidental connection :

The main therapeutic goal of modern cardiology is to develop novel approaches to minimize inflammation, myocardial necrosis/apoptosis, and enhance cardiac repair after MI. Though MI can be affected by genetic and environmental factors, the search for targeting lifestyle factors has been of greater interest. One such potential factor is the microbiota, the human intestinal microbial community. the disruption of intestinal flora structure provokes MI and poor prognosis. Since gut microbiota is readily modifiable through a variety of interventions, it can be targeted to modulate the host signaling pathways involved in inflammation and MI pathogenesis. Symbiosis bacteria can reduce ischemia/reperfusion injury and inflammation; moreover, they can regulate lipid metabolism, blood pressure, apoptosis, MI size, and overall cardiac survival. In this review, we provide an overview of the development of MI following the dysbiosis microbiota and give an update on a microbiota-based therapeutic strategy to delay or prevent MI.

Pharmacogenomics:

Pharmacogenomics can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose. Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and toxicity of many medications. Pharmacogenomic studies are rapidly elucidating the inherited nature of these differences in drug disposition and effects, thereby enhancing drug discovery and providing a stronger scientific basis for optimizing drug therapy on the basis of each patient's genetic constitution.

Bacteriocins and Antimicrobial Peptides –BAMP :

Antimicrobial peptides (AMPs) are ubiquitous, gene-encoded natural antibiotics that have gained recent attention in the search for new antimicrobials to combat infectious disease. In multicellular organisms, AMPs, such as defensins and cathelicidins, provide a coordinated protective response against infection and are a principal component of innate immunity in vertebrates.  In unicellular organisms, AMPs, such as bacteriocins, function to suppress competitor species. Because many AMPs kill bacteria by disruption of membrane integrity and are thus thought to be less likely to induce resistance, AMPs are being extensively evaluated as novel antimicrobial drugs 

Human Microbiota :

The collection of microbes living in and on our body - have a significant impact on human health and well-being. They have been associated with numerous diseases, yet we have barely understood their role in the context of life-style and genetics. Various initiatives are underway around the world to survey the human microbiota at several body sites, characterise them, understand their interactions with the human hosts, elucidate their role in diseases, and design possible therapeutic or dietary interventions.

Microbiota in early life shapes the immune system :

Microbial colonization of mucosal tissues during infancy plays an instrumental role in the development and education of the host mammalian immune system. These early-life events can have long-standing consequences: facilitating tolerance to environmental exposures or contributing to the development of disease in later life, including inflammatory bowel disease, allergy, and asthma. Recent studies have begun to define a critical period during early development in which disruption of optimal host-commensal interactions can lead to persistent and in some cases irreversible defects in the development and training of specific immune subsets. .

Gut Microbiota :

The complex community of microorganisms that live in the digestive tracts of humans and other animals, including insects. The gut metagenome is the aggregate of all the genomes of gut microbiota. The gut microbiota plays a key role in digestion, metabolism and immune function, and has widespread impact beyond the gastrointestinal tract. Changes in the biodiversity of the gut microbiota are associated with far reaching consequences on host health and development. Further understanding of the importance of developing and maintaining gut microbiota diversity may lead to targeted interventions for health promotion, disease prevention and management. Diet, functional foods and gut microbiota transplantation are areas that have yielded some therapeutic success in modulating the gut microbiota, and warrant further investigation of their effects on various disease states.

Modulation of Microbiota :

Microbiota modulation appears as an interesting tool in the prevention and/or treatment of the dysbiosis associated with obesity and metabolic disorders. Colonization of mucosal surfaces is characterized by fluctuating changes in microbial diversity during the first few years of life, until reaching a point of equilibrium that remains relatively stable throughout adulthood in the absence of environmental insults, immune maturation is likely influenced directly and/or indirectly by the presence of commensal microbes the early-life ecological succession of mucosal colonization occurs concomitantly with the development, expansion, and education of the mucosal immune system.   

Bioinformatics for Microbiome :

Microbes inhabit virtually all sites of the human body, yet we know very little about the role they play in our health. In recent years, there has been increasing interest in studying human-associated microbial communities, particularly since microbial dysbioses have now been implicated in a number of human diseases. Recent advances in sequencing technologies have made it feasible to perform large-scale studies of microbial communities, providing the tools. Rapidly developing sequencing methods and analytical techniques,  the human microbiome on different spatial and temporal scales, including daily time series datasets spanning months. Furthermore, emerging concepts related to defining operational taxonomic units, diversity indices, core versus transient microbiomes, are enhancing our ability to understand the human microbiome.

16S sequencing & Analysis :

16S ribosomal RNA (or 16S rRNA) is the component of the 30S small subunit of a prokaryotic ribosome that binds to the Shine-Dalgarno sequence.  16S rRNA sequencing has been used to characterize the complexity of microbial communities at each body sites, and to determine whether there is a core microbiome.The 16S rRNA sequence contains both highly conserved and variable regions. These variable regions, nine in number (V1 through V9), are routinely used to classify organisms according to phylogeny, making 16S rRNA sequencing particularly useful in metagenomics to help identify taxonomic groups present in a sample. 

Plant Conditioners [Biostimulants]:

Biostimulants may either directly interact with plant signaling cascades or act through stimulation of endophytic and non-endophytic bacteria, yeast, and fungi to produce molecules of benefit to the plant. These are the substances and materials with the exception of nutrients and pesticides, which, when applied to plant, seeds or growing substrates in specific formulations, have the capacity to modify the physiological processes of plants in a way that provides potential benefits to growth, development and/or stress response to enhance the nutrition efficiency and/or stress response.

Arbuscular mycorrhizal Fungi [AMF] :  

AMF support plant nutrition by absorbing and translocating mineral nutrients beyond the depletion zones of plant rhizosphere (biofertilisers) and induce changes in secondary metabolism leading to improved nutraceutical compounds. In addition, AMF interfere with the phytohormone balance of host plants, thereby influencing plant development (bioregulators) and inducing tolerance to soil and environmental stresses (bioprotector). Maximum benefits from AMF activity will be achieved by adopting beneficial farming practices (e.g. reduction of chemical fertilisers and biocides), by inoculating efficient AMF strains and also by the appropriate selection of plant host/fungus combinations.

Biostimulants and biocontrol strategies :

Biostimulants can be used as a tool to complement the use of chemical inputs, by involving non-living-based products, or living-based products Elicitors and semiochemicals are considered to be the most promising tools for inducing plant resistance to various diseases and enhancing natural predation, respectively. These tools are still difficult to use because of their lack of reliability in the field and their uneasy integration in the cropping systems. Maintaining these performances is supported by research through the development of new tools to increase the tolerance of plants to biotic and abiotic stresses.

Benefits Of Biostimulants :

"Biostimulants," often used in plural form, is a broad term that literally means a group of ingredients that stimulate life. Stimulate plant responses and work In all weather conditions, Increase microbial root protection from soil pathogens, Increase natural plant toxins, repelling pests, Improve drought tolerance, Stimulate plants' immune system, Detoxify chemical residues and heavy metals, Enhances fertilization and reduces leaching, Produce deeper roots, Improve stress tolerance, Accelerate establishment, Increase soil nutrient reserve, Increase profits, cut operating costs, lead to 50% reduction in fertilizer.

Horticulture hydroponics :

In horticulture, hydroponics is a form of agriculture where plants are not grown in soil, but rather in trays or grow beds fed by a constant flow of nutrient solution. A hydroponic system refers to the tools and equipment that are packaged together in order to grow plants hydroponically. Hydroponics is one the fastest rising sectors in the horticultural industry. It is, however, a contested one.

 

Market Analysis

The enormous amount of microorganisms that survive in and on the human body are referred as human microbiome. Scientists have suggested that these microorganisms play an important role in maintaining the digestive system, vitamin synthesis, immune system, and neurological system. Dysbiosis of Microbiome leads to metabolic disorder, Disease conditions, etc, therefore probiotics and related products are the main source for treating all the conditions provided by dysbiosis of microbiome.  The human microbiome market is expected to reach USD 899.1 Million by 2025 from USD 506.5 Million in 2022 growing at a CAGR of 21.1% during the forecast period (2022–2025).

 The human microbiome market is segmented on the basis of application, disease, product, and region. Also, the human microbiome research spending market is broadly segmented by product and technology.

Factors such as increased focus on human microbiome therapy, growing demand for human microbiomes as new validated targets for drug development, and the need for early disease detection and diagnosis are expected to drive the growth of the human microbiome market.

 Basis of disease :

This market comprises of obesity, diabetes, autoimmune disorders, acute diarrhea, cancer, mental disorders, and other diseases. In 2022, the acute diarrhea segment is expected to account for the largest share and is estimated to grow at the highest CAGR during the forecast period (2022–2025).

Basis of product :

This market is characterized into instruments and consumables. The instruments segment is further divided into laboratory instruments and analyzers, while, the consumables segment is further bifurcated into kits and reagents. The consumables segment is estimated to grow at the highest CAGR during the forecast period (2016–2021) owing to the repeated purchases of consumables as compared to instruments.

Basis of technology :

This market is divided into cell culture technology, high-throughput technology, omics technology, and computational tools. The cell culture technology segment is expected to account for the largest share of the global human microbiome research spending technology market in 2016. The large share can be attributed to the increasing R&D initiatives in the field of human microbiome.

· Europe is expected to account for the largest share of the global human microbiome market in 2022.

· In North America, the human microbiome market, in terms of value, is expected to be smaller as compared to       Europe.

· The key players in the human microbiome market are Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel (U.S.), and Merck (U.S.).

· MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals.

The global biostimulants market was valued at USD 1.79 Billion in 2016; this market is projected to reach USD 3.29 Billion by 2022, at a CAGR of 10.43% from 2017 to 2022. The biostimulants market has been segmented on the basis of crop type, form, application method, and active ingredient. It has been further segmented on the basis of region into North America, Europe, South America, Asia Pacific, and the Rest of the World (RoW). 

This report includes estimations of market sizes for value (USD million) with the base year as 2016 and forecast period from 2017 to 2022. Top-down and bottom-up approaches have been used to estimate and validate the size of the biostimulants market and to estimate the size of various other dependent submarkets. Key players in the market have been identified through secondary sources such as the European Biostimulant Industry Council (EBIC) and Biostimulant Coalition, and their market share in respective regions have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and were verified through primary sources.

The market is in its introductory stage, and the market was valued at USD 1,220.73 million in 2013. The market is projected to register a CAGR of 13.58% during the forecast period, 2017-2022, and is estimated to reach USD 3688.75 million by 2022.

· Europe is the largest market accounting for around 42% of the total market share. Growth in the consumption of organic food is driving the market in this region.

· The North American biostimulants industry accounts for around quarter of the market. 

· Investments in R&D by the governments and major players are expected to boost growth in the market during the forecast period.

· Asia-Pacific is estimated to be the fastest-growing region, India, China and Australia are the major markets in Asia-Pacific. 

Market Dynamics :

The factors that are driving a rapid growth in the biostimulants industry are expansion of the organic food industry, which is growing at a healthy rate, higher benefits associated with enhanced agricultural yield and productivity. The major constraints that are inhibiting the growth in the biostimulants industry include lower awareness rate among the farmers in developing countries and high R&D cost involved. An increase in the government support, in the form of subsidies, is one of the major opportunities for further growth of the biostimulants market.

Major Companies in the Sector Include :

  • Arysta Lifescience Corporation
  • Lallemand Plant Care
  • Isagro S.P.A.
  • Valagro SPA
  • Lallemand
  • ADAMA
  • Monsanto

Recent Industry Insights :

·  Investment in R&D of cheap & effective products is another strategy adopted by market leaders.

·  The major players in the market are Arysta LifeScience Corporation, Lallemand Plant Care, Isagro S.P.A, etc.

.   Arysta LifeScience, in order to reaffirm its position as a global leader in biostimulants.

To Collaborate Scientific Professionals around the World

Conference Date October 15-16, 2018

For Sponsors & Exhibitors

sponsors@conferenceseries.com

Speaker Opportunity

Supported By

Journal of Medical Microbiology & Diagnosis Journal of Bacteriology & Parasitology Journal of Plant Pathology & Microbiology Journal of Microbial & Biochemical Technology

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by


Media partners & Collaborators & Sponsors

mediapartner

Media Partner

mediapartner

Media Partner